Annals of the Rheumatic Diseases 1986, 45, 966-968 Correspondence Joint scintigraphy and erosions SIR, Isotope studies have been widely used in rheumatology for about 20 years. The study by Desaulniers and coworkers indicated that skeletal scintigraphy was a more sensitive method for the detection of inflammatory joint disease than radiography.' It appeared to be more sensitive than clinical evaluation in the diagnosis of joint inflammation of wrists, hands, ankles, and feet. We read with interest the study of Pitt, Berry, Clarke, and coworkers, in which x rays and joint scans with "mTc methylene diphosphonate (v9mTc MDP) were compared.2 They found no association between the uptake of isotope in the hands and the development of new erosions.
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They studied 10 patients with RA whose hands were x rayed at 0 and 12 months, whereas "mTc MDP scanning was performed only at the beginning of the study. Five patients had 30 eroded joints, 57% of which were scintigraphically active. The high proportion of scintigraphically negative erosions at the start of the study is not surprising since patients with early RA were not included. Five eroded joints in four patients with RA were found initially, and they were all scintigraphically active. All 72 joints in which new erosions developed during the follow up were also active by scanning. There were 85 scintigraphically highly active joints, 45 of which eroded during the follow up (Table 1) . When isotope activity remained normal in serial scannings new erosions were not discovered in the joints. Eleven joints with new erosions were initially scintigraphically inactive, but the activity increased during the follow up.
The clinical assessment could not predict erosiveness in 27 joints, while 'mTc MDP scanning missed only four. The calculated sensitivity and specifity of the methods in predicting erosions were 94-4% and 77-3% by 9"mTc MDP scanning and 62-5% and 85-7% by clinical assessment. Our patients suffered from active RA and the scanning was performed three times during 18 months. This could account for the difference between the results of Pitt et al and our study. The gammacamera used by Pitt and others was interfaced to a computer system, and the average count density in the joint was compared with background counts per unit area. In our study the measurement was performed visually, which is known to have a good correlation with the method of region of interest. 4 We conclude that serial imum score 4, using a similar scoring system and visual assessment ( Table 1) .
The results support our original report, showing no apparent association between the uptake of isotope and the development of erosions. Even when nine patients with early disease (mean 20 months) were examined a similar pattern of isotope uptake was found.
It is possible that the high proportion of joints reported by the above authors, showing increased uptake, reflects increased disease activity. We note that 47% of these highly active joints on isotope scanning have not developed erosions during the study.
We believe our original observation that increased uptake of isotope may be associated with some, but not all erosions, still stands and that isotope uptake probably reflects other processes of acute inflammation unassociated with the development of an erosion. If the hepatic enzyme rises are accepted as probably drug induced, however, there is a more important aspect to note, namely the lack of a clinical hypersensitivity reaction. All but one' of the 17 cases in the literature of sulphasalazine hepatotoxicity in inflammatory bowel disease showed such a reaction, comprising fever, lymphadenopathy, and peripheral eosinophilia. We wish to draw your readers' attention to another rheumatoid patient who developed sulphasalazine hepatotoxicity, in whom this hypersensitivity reaction was also notably absent.
Case history
A 50 year old woman with rheumatoid arthritis developed anorexia, nausea, and upper abdominal pain after 11 weeks of sulphasalazine therapy at a dose of 3 g/day. She was anicteric and had no fever, lymphadenopathy, skin rash, or any stigmata of liver disease. Hepatic transaminases, which had been normal immediately before treatment, were now markedly raised (see Table) . There was no history of jaundice, hepatitis contact, or blood transfusion, she had not travelled abroad, and her only other medication was ketoprofen, which she had been receiving for 18 months. Screening for hepatitis A and B, cytomegalovirus, EpsteinBarr, and herpes simplex viruses was negative. Upper abdominal ultrasound was normal, and antibodies to smooth muscle and mitochondria were not detected. A liver biopsy showed a severe acute hepatitis with focal 
